Ourobionics develops and produces complex human tissue models embedded with biosensors for high biomimicry. These cyborganic tissues provide real-time physiological and biomechanical output for research applications. The technology aims to accelerate drug discovery, reduce pharmaceutical R&D costs, and replace animal testing.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods for testing pharmaceutical compounds and cosmetic ingredients often rely on animal models, which can be ethically problematic, costly, and may not accurately reflect human physiological responses. This reliance can lead to slower drug discovery timelines and increased research and development expenses.
Solution
Ourobionics develops and produces advanced human tissue models integrated with biosensors, offering a high-fidelity, biomimetic alternative to animal testing. These cyborganic tissues provide real-time physiological and biomechanical data, enabling more accurate compound efficacy and safety assessments. By leveraging proprietary biofabrication technology, Ourobionics aims to accelerate drug discovery, reduce R&D costs, and improve the translational value of preclinical studies. The platform facilitates a deeper understanding of disease mechanisms and the development of novel therapeutic agents.
Target Audience
The primary customers are companies within the pharmaceutical, cosmetic, chemical, and Medtech sectors that require advanced in vitro testing solutions for compound evaluation and new product development.
Features
- High-throughput, complex human tissue structures engineered with embedded biosensors.
- Real-time monitoring of physiological and biomechanical processes within the tissue models.
- Proprietary CHIMERA biofabrication platform utilizing electric field technologies for enhanced cell viability and functionality.
- Tailorable tissue models for specific applications in pharmaceutical, cosmetic, chemical, and Medtech industries.
- Biomimetic design to improve the accuracy of compound testing compared to traditional methods.
- Focus on reducing ethical concerns and improving the translational value of preclinical research.